Prostate cancer at the 2007 ASCO meeting: an urologist's perspective [0.03%]
2007年ASCO会议前列腺癌研究进展：一位泌尿科医生的见解
N Mottet
N Mottet
During the last ASCO meeting in Chicago, multiple presentations focused on prostate cancer. Several prognostic factors have been developed, either at the initial stage or early during treatment. At the localized stage, the change in prostat...
[Surgical treatment of ureteropyelic junction stenosis using robotic-assisted laparoscopy] [0.03%]
机器人辅助腹腔镜下肾盂输尿管连接部狭窄手术治疗报告
C Egrot,J Hubert
C Egrot
Since the introduction of mini-invasive surgery approximately thirty years ago, Laparoscopic surgery has significantly evolved both in terms of its extended field of application and of the tools used which were diversified and improved. Mor...
J Hubert
J Hubert
Born in the late 90s, robotic-assisted laparoscopy has today an exponential growth. It presents some disadvantages, the first of them being a very high cost, similarly to all new medical technologies. On the other hand, its advantages are v...
J F Hétet,J Rigaud,M Dorel-Le Théo et al.
J F Hétet et al.
Kidney cancer occurs rarely and late in renal transplants. The lack of grafts and the increasing age of the cadaver donors are likely to result in an increasing number of such cancers. To date, the treatment of choice is the transplant remo...
C Legendre,J Zuber,D Anglicheau et al.
C Legendre et al.
Kidney transplantation has become the treatment of choice in end-stage chronic renal failure since it significantly improves both the quality of life and the life duration of affected patients, when compared with dialysis. Some of these bet...
G Karam,F Maillet,G Braud et al.
G Karam et al.
Kidney transplantation has become the treatment of choice for patients with end stage renal disease since it offers an excellent quality of life. Moreover, the economic impact is considerable, particularly beyond the first year. Indeed, the...
A Bouregba,T Lebret
A Bouregba
Prostate cancer, particularly advanced prostate cancer, should be considered as a chronic disease that requires multidisciplinary management. Each health professional involved the urologist of course, but also the other therapists, especial...
M Zerbib
M Zerbib
The contribution of LHRH analogs is enormous in prostate cancer management at nearly all stages of the disease, the Leading cancer in males over 50 years of age. They make it possible to use hormone therapy reliably, with Little morbidity, ...
J F Bergmann
J F Bergmann
The quality of a therapeutic trial depends on several parameters. The ideal trial in prostate cancer should be a high-quality trial on a well-defined and significant population. The method used to calculate the number of subjects necessary ...
K Fizazi
K Fizazi
Chemotherapy is one the therapeutic options in prostate cancer. Docetaxel once every three weeks is the current standard for castration-refractory disease with cancer-related symptoms. The docetaxel plus estramustine association is likely m...